GlobalData on MSN4mon
Oncoinvent doses first subject in Phase II ovarian cancer treatment trialOncoinvent has dosed the first subject in the Phase II clinical trial of Radspherin, an alpha-radiation therapy, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback